Starting mid-October 2020, the Ontario publicly-funded shingles immunization program, available for Ontario seniors ages 65 to 70 years, will begin to transition from funding the Zostavax® II (Merck Canada Inc.) vaccine to funding the Shingrix® (GSK) vaccine. Shingrix® is a recombinant subunit, adjuvanted vaccine indicated for prevention of Herpes Zoster (shingles) and is provided as a 2-dose immunization series.
